List of Excipients in Branded Drug XIPERE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch & Lomb Incorporated	XIPERE	triamcinolone acetonide	24208-040	CALCIUM CHLORIDE
Bausch & Lomb Incorporated	XIPERE	triamcinolone acetonide	24208-040	CARBOXYMETHYLCELLULOSE SODIUM
Bausch & Lomb Incorporated	XIPERE	triamcinolone acetonide	24208-040	HYDROCHLORIC ACID
Bausch & Lomb Incorporated	XIPERE	triamcinolone acetonide	24208-040	MAGNESIUM CHLORIDE
Bausch & Lomb Incorporated	XIPERE	triamcinolone acetonide	24208-040	POLYSORBATE 80
Bausch & Lomb Incorporated	XIPERE	triamcinolone acetonide	24208-040	POTASSIUM CHLORIDE

XIPERE Excipient Strategy and Commercial Opportunities

Last updated: August 30, 2026

XIPERE is a differentiated ophthalmic suspension built around triamcinolone acetonide, a short-chain excipient system, and suprachoroidal delivery through Clearside Biomedical's proprietary SCS Microinjector. The formulation opportunity is less likely to come from replacing a single excipient than from reproducing the product's particle-size distribution, suspension stability, syringeability, sterility profile, dose uniformity, and device compatibility. Commercial value is concentrated in the combination of formulation, delivery system, manufacturing process, and clinical-use patents rather than in the inactive ingredients alone.[1][2]

What is XIPERE and how is it delivered?

XIPERE is triamcinolone acetonide injectable suspension for suprachoroidal use. The FDA approved it in October 2021 for the treatment of macular edema associated with uveitis.[1]

The product is administered with the SCS Microinjector, which delivers the suspension into the suprachoroidal space rather than by conventional intravitreal injection. This route is intended to place corticosteroid near the choroid and retina while limiting exposure to other ocular tissues.[1][3]

Attribute	XIPERE profile
Active ingredient	Triamcinolone acetonide
Strength	40 mg/mL
Dosage form	Injectable suspension
Route	Suprachoroidal
Indication	Macular edema associated with uveitis
FDA approval	October 2021
Sponsor/developer	Clearside Biomedical
U.S. commercial partner	Bausch + Lomb
Delivery technology	SCS Microinjector
Preservative status	Single-dose ophthalmic product; no antimicrobial preservative is identified in the listed inactive ingredients

XIPERE's commercial differentiation depends on the delivery route. A formulation that is chemically equivalent but cannot be delivered through the SCS Microinjector may not provide a direct substitute.

What excipients are used in XIPERE?

The FDA prescribing information identifies four inactive ingredients in XIPERE: carboxymethylcellulose sodium, polysorbate 80, sodium chloride, and water for injection.[1]

Excipient	Reported role in XIPERE
Carboxymethylcellulose sodium	Suspending and viscosity-modifying agent
Polysorbate 80	Wetting and surface-stabilizing surfactant
Sodium chloride	Tonicity adjustment
Water for injection	Vehicle

The labeled composition per milliliter includes 40 mg of triamcinolone acetonide, 5 mg of carboxymethylcellulose sodium, 0.4 mg of polysorbate 80, and 8.5 mg of sodium chloride, with water for injection as the vehicle.[1]

Why carboxymethylcellulose matters

Carboxymethylcellulose sodium is likely the central formulation excipient because it controls suspension behavior. Its concentration affects:

• Sedimentation rate
• Redispersibility
• Particle aggregation
• Injection force
• Residence time after suprachoroidal administration
• Dose uniformity between withdrawn doses
• Compatibility with the microinjector

A generic developer cannot treat carboxymethylcellulose as a simple one-for-one substitute. Molecular weight distribution, degree of substitution, viscosity grade, impurity profile, and supplier-to-supplier variability can change the finished product's performance.

Why polysorbate 80 matters

Polysorbate 80 improves wetting of the hydrophobic triamcinolone acetonide particles and can reduce aggregation during manufacture and storage. Its concentration must be controlled closely because excessive surfactant can affect:

• Particle-surface interactions
• Subvisible particle formation
• Oxidative degradation
• Container closure compatibility
• Ocular tolerability
• Suspension uniformity

Polysorbate 80 is also subject to peroxide and degradation-product concerns. A commercial formulation strategy should include tight control of raw-material grade, peroxide value, storage conditions, and interaction with elastomeric components.

Why sodium chloride matters

Sodium chloride is used to adjust tonicity. In a suprachoroidal product, tonicity control has commercial and regulatory importance because local tolerability is directly connected to the physicochemical environment at the injection site. Changes in sodium chloride concentration could alter osmolality, tissue tolerance, suspension behavior, or the drug's interaction with the delivery system.

What formulation attributes are commercially difficult to copy?

The core barrier is not the public identity of the excipients. The barrier is the finished suspension's critical quality attributes.

Particle size and morphology

Triamcinolone acetonide is a poorly water-soluble corticosteroid administered as a suspension. Particle size affects dissolution, tissue distribution, sedimentation, and duration of local exposure. A competitor would need to establish a controlled particle-size distribution and demonstrate that the product is clinically equivalent or sufficiently comparable.

Relevant development controls include:

• D10, D50, and D90 particle-size values
• Particle morphology
• Crystal form and polymorphism
• Agglomerate content
• Sedimentation volume
• Redispersibility
• Subvisible particle burden

The active ingredient's crystal habit may be as commercially important as the excipient composition.

Suspension uniformity

XIPERE is supplied as a suspension, creating a dose-uniformity risk that does not arise to the same extent with a clear solution. The product must remain adequately dispersed during shipping, storage, preparation, and administration. A formulation with acceptable assay but poor resuspendability can produce inconsistent dosing.

Device compatibility

The SCS Microinjector creates a separate development barrier. Viscosity, particle size, syringe dimensions, needle geometry, plunger force, and dead volume must operate within a narrow range. The formulation must pass through the device without clogging, excessive force, particle retention, or dose loss.[3]

This creates an opportunity for device-linked intellectual property. A competitor could potentially develop a different suprachoroidal injector, but that would require separate usability, sterility, performance, and clinical validation work.

What patents protect XIPERE?

XIPERE is protected through a layered estate covering suprachoroidal administration, delivery devices, formulations, and therapeutic use. The public product description does not establish that the individual inactive ingredients are proprietary. The strongest protection is more likely to arise from the combination of:

1. Triamcinolone acetonide suspension characteristics.
2. Suprachoroidal delivery for uveitic macular edema.
3. The SCS Microinjector or related delivery architecture.
4. Manufacturing controls that produce a clinically consistent suspension.
5. Method-of-use claims covering treatment of retinal or choroidal disorders.

Are the excipients themselves patent-protected?

The named excipients are established pharmaceutical materials and are not, by themselves, a meaningful exclusivity barrier. Patent value may arise from:

• Defined concentration ranges
• Specific viscosity windows
• Particle-size limits
• Suspension stability parameters
• Surfactant-to-drug ratios
• Device-compatible rheology
• Manufacturing processes
• Combination claims covering the suspension and injector

A formulation patent that claims a narrow composition can be vulnerable if a competitor develops a different excipient system with comparable performance. A broader patent that claims delivery of a corticosteroid suspension into the suprachoroidal space may create greater commercial risk.

What is the Orange Book status of XIPERE?

XIPERE is an approved drug product associated with NDA 214955. The FDA Orange Book is the controlling source for current patent-listing and exclusivity information.[4] The FDA label identifies the approved composition and use, but it does not establish a complete patent-expiration analysis.

For commercial planning, the relevant questions are:

• Which patents are currently listed for NDA 214955?
• Are listed patents directed to the drug, formulation, method of use, or delivery system?
• Do the listings create a Paragraph IV certification pathway?
• Does the ANDA applicant need a device-specific product-development strategy?
• Are any listed claims vulnerable to invalidity or non-infringement arguments?

Patent expiration should be assessed patent by patent. A single headline expiration date would not accurately describe XIPERE's protection because device, method-of-use, formulation, and manufacturing patents may expire at different times.

When did XIPERE lose regulatory exclusivity?

XIPERE was approved on October 25, 2021. Because triamcinolone acetonide is an established active ingredient, the product was not approved as a new chemical entity. The likely FDA marketing-exclusivity framework is three-year exclusivity based on new clinical investigations supporting approval, rather than five-year NCE exclusivity.[1][5]

That exclusivity period would generally have ended in October 2024, subject to the precise FDA exclusivity designation and any applicable regulatory adjustments. Regulatory exclusivity does not eliminate patent protection. An ANDA applicant may still face listed-patent barriers after the expiration of the three-year period.

What generic entry risks exist for XIPERE?

Generic entry risk is moderate to high over the long term, but it is technically more complex than a conventional ophthalmic suspension.

Paragraph IV risk

A prospective ANDA applicant could challenge listed patents through a Paragraph IV certification. Potential positions could include:

• The asserted patent is invalid.
• The proposed product does not infringe.
• The patent is not enforceable.
• The applicant's formulation or injector avoids the claimed concentration, particle-size range, or device structure.

The sponsor could respond with patent litigation under the Hatch-Waxman framework. A timely patent action can trigger a 30-month stay of FDA approval, subject to statutory conditions and court developments.[6]

Product-specific equivalence risk

An ANDA applicant would need to address more than chemical composition. Key issues include:

• Active ingredient sameness
• Strength and dosage form
• Sterility
• Particle-size distribution
• Redispersibility
• Viscosity
• Delivered dose
• Device performance
• Injection force
• Container closure integrity
• Local ocular safety

If the product is not suitable for an ordinary ANDA, a 505(b)(2) pathway could become relevant, particularly for a modified formulation, alternative injector, or changed route-of-administration profile.[5]

Biosimilar risk

Biosimilar risk is not applicable. XIPERE contains triamcinolone acetonide, a small-molecule corticosteroid, rather than a biologic. Competitive entry would occur through generic or 505(b)(2) pathways, not through the abbreviated biosimilar pathway.

What commercial opportunities exist in XIPERE's excipient strategy?

Excipient-supplier opportunity

Suppliers can compete for pharmaceutical-grade materials that improve:

• Low-peroxide polysorbate 80 performance
• Carboxymethylcellulose consistency
• Reduced particulate burden
• Improved suspension stability
• Better device passage
• Longer refrigerated or controlled-room-temperature stability

The most valuable supplier position would be a qualified grade supported by formulation data, not commodity supply alone.

Alternative formulation opportunity

A rival product could explore:

• Alternative cellulose derivatives
• Nonionic surfactants other than polysorbate 80
• Steric stabilizers
• Reduced-viscosity systems
• Controlled-release microparticles
• Nanocrystal or microcrystal suspensions
• Preservative-free multidose architectures
• Lyophilized products reconstituted before injection

Each approach would need to preserve suprachoroidal injectability and clinical exposure. A novel excipient system could create freedom-to-operate advantages if it avoids composition claims in the incumbent estate.

Combination-product opportunity

A competing injector could target:

• Easier procedure preparation
• Lower injection force
• More consistent suprachoroidal placement
• Reduced reflux
• Improved tactile feedback
• Smaller dead volume
• Lower manufacturing cost
• Compatibility with multiple ophthalmic suspensions

This strategy could compete with XIPERE without copying its exact formulation.

Manufacturing opportunity

The product requires robust controls for sterile suspension manufacture. Contract manufacturing opportunities may exist in:

• Micronization and particle engineering
• Aseptic suspension compounding
• Low-shear blending
• Sterile filling
• Container closure systems
• Device assembly
• Stability testing
• Subvisible particle characterization

Manufacturing know-how may create a practical barrier even when the formulation appears simple from the public label.

How does XIPERE compare with competing corticosteroid therapies?

Product or approach	Route	Active ingredient	Main differentiation
XIPERE	Suprachoroidal	Triamcinolone acetonide	Targeted delivery through SCS Microinjector
Intravitreal triamcinolone products	Intravitreal	Triamcinolone acetonide	Established corticosteroid route, different exposure profile
Ozurdex	Intravitreal implant	Dexamethasone	Sustained-release biodegradable implant
Retisert	Intravitreal implant	Fluocinolone acetonide	Long-duration corticosteroid delivery
Iluvien	Intravitreal implant	Fluocinolone acetonide	Extended-release implant for selected retinal disease

XIPERE competes on route and treatment profile rather than on excipient novelty alone. Its principal commercial advantages are targeted suprachoroidal placement and a suspension-based administration format. Its disadvantages include procedural complexity, device dependence, and the need for specialized physician training.

What litigation and settlement issues affect XIPERE?

A complete litigation assessment requires current docket and Orange Book data. The commercial exposure would center on four areas:

1. Paragraph IV litigation involving listed formulation, method-of-use, or device patents.
2. Patent disputes over suprachoroidal delivery.
3. Contract disputes involving the Clearside-Bausch + Lomb commercialization arrangement.
4. Trade-secret or manufacturing disputes involving suspension processing and device assembly.

Publicly available FDA materials establish approval and labeling, but they do not by themselves establish the existence of a settlement agreement, authorized generic arrangement, or final litigation outcome. Those issues must be tied to current court and regulatory records before being used in valuation or launch modeling.

Key Takeaways

• XIPERE uses triamcinolone acetonide 40 mg/mL with carboxymethylcellulose sodium, polysorbate 80, sodium chloride, and water for injection.
• The formulation's commercial value lies in suspension performance, not in the ordinary identity of the excipients.
• Particle size, redispersibility, viscosity, sterility, and device compatibility are central development barriers.
• The SCS Microinjector creates a device-linked barrier that can limit direct generic substitution.
• XIPERE's likely three-year regulatory exclusivity period ran from the October 2021 approval and generally ended in October 2024.
• Biosimilar competition is irrelevant because triamcinolone acetonide is a small molecule.
• The strongest competitive opportunities are alternative suspension systems, injector platforms, particle-engineering technologies, and specialized sterile manufacturing.
• Patent risk should be evaluated across formulation, method-of-use, device, and manufacturing claims rather than through a single expiration date.

FAQs

Can a company copy XIPERE's excipients and launch a generic product?

Copying the listed excipients does not establish equivalence. The applicant would also need to address particle size, suspension stability, sterility, dose uniformity, device performance, and applicable patents.

Is XIPERE a combination product?

XIPERE is administered with the SCS Microinjector, making the delivery system commercially important. The regulatory classification and any device-specific requirements depend on the FDA product record and the proposed competing product.

Could a preservative-free alternative compete with XIPERE?

Potentially. A preservative-free alternative could compete if it demonstrates sterility, stability, local tolerability, dose uniformity, and comparable clinical performance.

Is triamcinolone acetonide subject to biosimilar competition?

No. Triamcinolone acetonide is a small-molecule active ingredient. Competition would proceed through generic or 505(b)(2) pathways.

What is the most valuable IP around XIPERE?

The highest-value protection is likely to involve the integrated product system: suprachoroidal delivery, injector design, suspension attributes, method of treatment, and manufacturing controls.

References

1. U.S. Food and Drug Administration. (2021). XIPERE (triamcinolone acetonide injectable suspension) prescribing information.
2. Clearside Biomedical, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
3. Clearside Biomedical, Inc. (n.d.). SCS Microinjector technology and XIPERE product information.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Food and Drug Administration. (2024). 505(b)(2) applications and abbreviated new drug applications: Regulatory guidance.
6. U.S. Code. (2024). 21 U.S.C. § 355, New drug applications and abbreviated applications.